1. Home
  2. VPG vs GYRE Comparison

VPG vs GYRE Comparison

Compare VPG & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VPG

Vishay Precision Group Inc.

HOLD

Current Price

$126.19

Market Cap

552.5M

Sector

Technology

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$6.11

Market Cap

573.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VPG
GYRE
Founded
2009
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
552.5M
573.4M
IPO Year
2010
2004

Fundamental Metrics

Financial Performance
Metric
VPG
GYRE
Price
$126.19
$6.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$53.50
$17.00
AVG Volume (30 Days)
652.6K
85.3K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$307,202,000.00
$275,000.00
Revenue This Year
$7.21
$19.88
Revenue Next Year
$6.92
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.22
N/A
52 Week Low
$25.49
$5.44
52 Week High
$136.21
$9.42

Technical Indicators

Market Signals
Indicator
VPG
GYRE
Relative Strength Index (RSI) 76.00 42.18
Support Level $32.38 N/A
Resistance Level N/A $8.13
Average True Range (ATR) 9.99 0.30
MACD 0.85 -0.02
Stochastic Oscillator 78.55 43.60

Price Performance

Historical Comparison
VPG
GYRE

About VPG Vishay Precision Group Inc.

Vishay Precision Group Inc manufactures and markets sensors and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: